Duchenne muscular dystrophy (DMD) follows an X-linked recessive inheritance pattern. Because the gene responsible sits on the X chromosome, the condition overwhelmingly affects boys, occurring in roughly 20 per 100,000 live male births worldwide. Girls can carry the mutation and, in some cases, experience mild symptoms, but severe disease in females is rare.
Why Boys Are Almost Always Affected
Males have one X chromosome and one Y chromosome. If a boy inherits an X chromosome carrying a faulty copy of the dystrophin gene, he has no second X to compensate. His body cannot produce functional dystrophin, the protein that acts as a shock absorber for muscle fibers during contraction. Without it, muscles progressively break down.
Girls have two X chromosomes. If one carries the mutation, the other typically produces enough dystrophin to keep muscles functioning. This is why girls who inherit the mutation are usually carriers rather than patients. About 8% of female carriers do develop some degree of muscle weakness, however, and are called manifesting carriers. Their symptoms tend to be milder and often asymmetrical, affecting one side of the body more than the other. A muscle biopsy in these women shows a characteristic mosaic pattern: some fibers produce dystrophin normally while others do not.
What Causes the Gene to Malfunction
The dystrophin gene is located on the short arm of the X chromosome at a position called Xp21.1. It is one of the largest genes in the human genome, which partly explains why it is so vulnerable to errors. In a study of 750 patients, about 71% had large deletions (missing chunks of genetic code), 10% had large duplications (repeated segments), and 15% had point mutations (single-letter errors in the DNA sequence). Deletions cluster most often between exons 45 and 55, while duplications tend to occur between exons 2 and 23.
The type of mutation matters for prognosis and treatment eligibility. Deletions that shift the reading frame of the gene tend to produce no functional dystrophin at all, leading to the severe Duchenne form. Mutations that preserve the reading frame often allow a shortened but partially functional protein, resulting in the milder Becker muscular dystrophy instead.
Inherited vs. Spontaneous Mutations
Not every case of DMD is passed down from a carrier mother. About one-third of cases arise from new (de novo) mutations, meaning no one else in the family carries the genetic change. When researchers break this down more precisely, roughly 68% of sporadic cases trace back to a mother who is a confirmed carrier, about 19% involve germline mosaicism in the mother (the mutation exists in some of her egg cells but not in her blood cells, so standard testing may miss it), and 13% represent a completely new mutation that occurred in the affected boy himself.
Germline mosaicism is a particularly important concept for families. A mother whose blood test comes back negative for carrier status might still have the mutation in a fraction of her eggs. For these women, the recurrence risk is not zero. Estimates place it at roughly 4 to 9% overall, with some variation depending on where the deletion falls within the gene. Proximal deletions carry a higher recurrence risk (around 16%) than distal ones (around 6%).
Risks for a Carrier Mother’s Children
When a woman is a confirmed carrier, each pregnancy carries predictable odds. Every son has a 50% chance of inheriting the affected X chromosome and developing DMD. Every daughter has a 50% chance of inheriting the affected X and becoming a carrier herself. The father’s genetic contribution does not change these probabilities because the mutation is on the X chromosome, and fathers pass their Y chromosome to sons and their X to daughters.
These are per-pregnancy risks. Having one unaffected son does not change the odds for the next pregnancy. This is why genetic counseling and prenatal or preimplantation testing are commonly discussed with families once a diagnosis is made.
How Carrier Status Is Identified
Identifying female carriers in a family typically starts with knowing the specific mutation found in the affected boy. If his mutation is a deletion or duplication, a technique called multiplex ligation-dependent probe amplification (MLPA) is the preferred first-line test for female relatives. MLPA measures the number of copies of each segment of the dystrophin gene, detecting whether a woman has one normal copy and one deleted or duplicated copy.
When the affected male has a point mutation or small insertion, direct gene sequencing is used instead. In families where the exact mutation is unknown, linkage analysis can estimate carrier status by tracking genetic markers that sit near the dystrophin gene through the family tree. This approach requires DNA samples from multiple relatives and is less definitive, but it can still provide useful probability estimates.
Blood levels of creatine kinase, an enzyme released by damaged muscle, are elevated in many carriers but not all. A normal creatine kinase level does not rule out carrier status, and an elevated level does not confirm it. Genetic testing is far more reliable.
Why Family History Alone Can Be Misleading
Because roughly a third of DMD cases appear with no prior family history, a negative family history does not mean there is no genetic risk for future pregnancies. Germline mosaicism can hide in a mother who tests negative on standard blood-based genetic screening. For this reason, genetic counselors often recommend that mothers of boys with apparently spontaneous DMD still undergo careful evaluation, including testing for the specific mutation and, in some cases, prenatal testing in subsequent pregnancies regardless of their own carrier test results.
Sisters and maternal aunts of affected boys also carry meaningful risk of being carriers and can benefit from genetic testing, particularly before planning pregnancies of their own. The further the family relationship from the affected individual, the lower the prior probability of carrier status, but testing remains the only way to know with confidence.